Open Heart

APRIL 15, 2022

Background Currently, potent P2Y 12 inhibition with the use of prasugrel or ticagrelor is the mainstay of treatment after an acute coronary syndrome (ACS). The 2020 European Society of Cardiology (ESC) Guidelines recommend the use of prasugrel over ticagrelor in patients with non-ST-elevation ACS (NSTE-ACS) intended to receive invasive management (class IIa recommendation), however there are contradictory views regarding this recommendation.

Myocardial Infarction 52

Myocardial Infarction Thrombosis Stent Stents 52

EMS 12-Lead

APRIL 14, 2022

David Didlake, NRP, APRN, ACNP-BC This case is provided by C. Madden, Paramedic. Many thanks for sharing! A 48 y/o Male called 911 after experiencing sudden onset chest discomfort while performing yard work. He presented to EMS with extreme pallor, Levine sign, diaphoresis, bilateral arm pain, and an apprehensive sense of doom. Past medical history included HTN, HLD, and MI 10 years prior.

ACE Inhibitor 52

ACE Inhibitor Physiology Chest Pain Academic 52

ECG Cases

APRIL 12, 2022

Tahara Bhate's new QI corner Quick Hits series, Hans Rosenberg & Michael Gottlieb on the evidence around ED diagnosis and management of skin abscesses using PoCUS, Anand Swaminathan on what the oxygen saturation monitor can tell you besides oxygen saturation, Sarah Reid on how to pick up infantile spasms and prevent poor neurologic outcomes, Elisha Targonsky on battle of the ED rate control medications for rapid atrial fibrillation.

Atrial Fibrillation 52

Atrial Fibrillation Outcomes 52

Penn Heart and Vascular Blog

APRIL 12, 2022

Ejection fraction is a measurement that can gauge how healthy the heart is.

40

40

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Patient Care

Open Heart

APRIL 11, 2022

Objective This study aimed to evaluate the prognostic value of hyperemic microvascular resistance (HMR) and its relationship with hyperemic stenosis resistance (HSR) index and fractional flow reserve (FFR) in stable coronary artery disease. Methods This is a substudy of the DEFINE-FLOW cohort (NCT02328820), which evaluated the prognosis of lesions (n=456) after combined FFR and coronary flow reserve (CFR) assessment in a prospective, non-blinded, non-randomised, multicentre study in 12 centres i

Coronary Artery Disease 52

Coronary Artery Disease Stenosis 52

Open Heart

APRIL 11, 2022

Background Body iron stores (BISs) have been proposed to be related to the development of cardiovascular diseases. However, results from epidemiological studies are conflicting. Knowledge on the long-term impact of BIS on cardiovascular outcomes in the general population is lacking. Purpose The aim of this study was to explore the relationship between BIS and coronary heart disease (CHD) including death due to CHD.

Heart Disease 52

Heart Disease Outcomes Biomarkers Cardiovascular Disease 52